Newswire (Published: Friday, October 4, 2019, Received: Friday, October 4, 2019, 4:31:17 PM CDT)
Word Count: 504
2019 OCT 04 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Daily -- Data detailed on Oncology - Prostate Cancer have been presented. According to news reporting originating in Heidelberg, Germany, by NewsRx journalists, research stated, “Defects in DNA damage repair caused by mutations in BRCA1/2, ATM or other genes have been shown to play an important role in the development and progression of prostate cancer. The influence of such mutations on anti-tumor immunity in prostate cancer, however, is largely unknown.”
Financial support for this research came from Medizinischen Fakultat Heidelberg, Universitat Heidelberg.
The news reporters obtained a quote from the research from the University of Heidelberg School of Medicine, “To better understand the correlation between BRCA1/2 mutations and the immune phenotype in prostate cancer, we characterized the immune infiltrate of eight BRCA2-mutated tumors in comparison with eight BRCA1/2 wild-type patients by T-cell receptor sequencing and immunohistochemistry for CD45, CD4, CD8, FOXP3, and CD163. In addition, we analyzed seven prostate cancer biopsies that were either BRCA2 or ATM-mutated in comparison with wild-type tumors. Whereas in BRCA1/2 wild-type tumors, immune cells were found predominantly extratumorally, most BRCA2-mutated tumors including one biopsy showed a significantly increased intratumoral immune cell infiltration. The ratio of intratumoral to extratumoral immune cells was considerably higher in BRCA2-mutated tumors for all markers and reached statistical significance for CD4 (p=0.007), CD8 (p=0.006), and FOXP3 (p=0.001). However, the intratumoral CD8 to FOXP3 ratio showed a trend to be lower in BRCA2-mutated tumors suggesting a more suppressed tumor immune microenvironment.”
According to the news reporters, the research concluded: “Our findings provide a rationale for the future use of immune oncological approaches in BRCA2-mutated prostate cancer and may encourage efforts to target immunosuppressive T-cell populations to prime tumors for immunotherapy.”
For more information on this research see: The BRCA2 mutation status shapes the immune phenotype of prostate cancer. Cancer Immunology, Immunotherapy, 2019;():. Cancer Immunology, Immunotherapy can be contacted at: Springer, 233 Spring Street, New York, NY 10013, USA. (Springer - www.springer.com; Cancer Immunology, Immunotherapy - http://www.springerlink.com/content/0340-7004/)
Our news correspondents report that additional information may be obtained by contacting A. Stenzinger, Institute of Pathology, University of Heidelberg School of Medicine, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany. Additional authors for this research include P. Keß, C. Nientiedt, V. Endris, M. Kippenberger, J. Leichsenring, F. Stogbauer, J. Haimes, S. Mishkin, B. Kudlow, A. Kaczorowski, S. Zschabitz, A.L. Volckmar, H. Sultmann, D. Jager, A. Duensing and P. Schirmacher.
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1007/s00262-019-02393-x. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
The publisher of the journal Cancer Immunology, Immunotherapy can be contacted at: Springer, 233 Spring Street, New York, NY 10013, USA.
(Our reports deliver fact-based news of research and discoveries from around the world.)
New York City
Science and Technology
Health and Wellness
Medical Conditions and Diseases
Men's Health Issues
Medical Specialties and Practices
Treatments and Therapies